Page 2 - Quantum Genomics News Today

Currently, much research is ongoing to develop new and effective therapeutic drugs for the treatment of Heart failure. The treatment of HF is dependent on...

Glutamyl Aminopeptidase Market to Eyewitness Massive Growth by 2030

Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical

Quantum Genomics gives an update Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly

Edema was seen in roughly 10% to 20% of patients, depending on the dose, but it was clinically manageable with diuretics.

Recent developments of interest in cardiovascular medicine

Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million...

Quantum Genomics Announces the Next Meeting of its Scientific and Clinical Committee Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development

Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development

Edison Investment Research Limited Quantum Genomics (ALQGC): Initiation A fresh take on cardiovascular medicine 31-Aug-2022 / 08:55 GM...